Physician profile
Paul Meltzer
NPI 1982609145
$2,313.44
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $301 · 2021: $441 · 2022: $316 · 2023: $328 · 2024: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $368.98 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $355.21 | 2019-2024 | Xarelto |
| Pfizer INC. | $206.30 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $185.36 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $177.80 | 2022-2024 | Camzyos, Eliquis |
| Novo Nordisk INC | $146.51 | 2022-2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $144.19 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.22 | 2021-2024 | Jardiance |
| Abbott Laboratories | $103.84 | 2021-2024 | Jot Dx |
| Boston Scientific Corporation | $76.67 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $75.01 | 2021 | |
| Biotronik INC. | $66.09 | 2020-2021 | |
| Recor Medical INC | $43.62 | 2024 | Paradise Renal Denervation System |
| Astrazeneca Pharmaceuticals Lp | $42.59 | 2022-2023 | Farxiga |
| Kestra Medical Technology Services, INC. | $38.85 | 2022-2024 | Assure Wcd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $38.41 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $37.92 | 2024 | Arcalyst |
| Sun Pharmaceutical Industries INC. | $25.04 | 2021 | |
| Scpharmaceuticals INC. | $19.74 | 2024 | |
| Esperion Therapeutics, INC. | $18.18 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $15.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Meltzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.